Scholarlink

<p>Ibrutinib is an oral targeted drug that has been approved by the US Food and Drug Administration (FDA) for the management of chronic lymphocytic leukemia (CLL), Waldenstrom’s macroglobulinemia, and previously treated chronic graft-versus-host disease. It is an irreversible selective inhibitor of Bruton’s tyrosine kinase (Btk)1. We report the case of a 54-year-old male patient, diagnosed with CLL being who was with ibrutinib. He developed several erythematous and&#xa0;indurated plaques on the neck, face, hands, and scalp, 8&#xa0;months into his treatment. Clinical features&#xa0;along with skin biopsy findings of a neutrophil predominant infiltrate were consistent with the diagnosis of Sweet syndrome. Upon withdrawal of the medication and application of a potent topical steroid, cutaneous lesions healed&#xa0;after one week. However, readministration of the medication at a lower dose was associated, with recurrence of the lesions, suggesting a temporal relationship with ibrutinib&#xa0;and necessitating drug discontinuation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ibrutinib-induced Sweet syndrome

  • 期刊论文

  • 发表日期：

    2026年5月8日

查看全文
  • Noor Almaani,
  • Zain Al Ta’ani,
  • Maram Abdaljaleel,
  • Faris AlShammas,
  • Alaa Alshorman

摘要

Ibrutinib is an oral targeted drug that has been approved by the US Food and Drug Administration (FDA) for the management of chronic lymphocytic leukemia (CLL), Waldenstrom’s macroglobulinemia, and previously treated chronic graft-versus-host disease. It is an irreversible selective inhibitor of Bruton’s tyrosine kinase (Btk)1. We report the case of a 54-year-old male patient, diagnosed with CLL being who was with ibrutinib. He developed several erythematous and indurated plaques on the neck, face, hands, and scalp, 8 months into his treatment. Clinical features along with skin biopsy findings of a neutrophil predominant infiltrate were consistent with the diagnosis of Sweet syndrome. Upon withdrawal of the medication and application of a potent topical steroid, cutaneous lesions healed after one week. However, readministration of the medication at a lower dose was associated, with recurrence of the lesions, suggesting a temporal relationship with ibrutinib and necessitating drug discontinuation.